Compare MGPI & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MGPI | LBRX |
|---|---|---|
| Founded | 1941 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 516.4M | 544.7M |
| IPO Year | 1988 | 2025 |
| Metric | MGPI | LBRX |
|---|---|---|
| Price | $24.25 | $21.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $40.00 | ★ $49.00 |
| AVG Volume (30 Days) | ★ 536.3K | 488.0K |
| Earning Date | 10-29-2025 | 02-15-2026 |
| Dividend Yield | ★ 1.98% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $578,855,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $21.67 | $13.36 |
| 52 Week High | $40.64 | $23.15 |
| Indicator | MGPI | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 46.73 | N/A |
| Support Level | $23.46 | N/A |
| Resistance Level | $24.32 | N/A |
| Average True Range (ATR) | 0.85 | 0.00 |
| MACD | -0.11 | 0.00 |
| Stochastic Oscillator | 22.43 | 0.00 |
MGP Ingredients Inc is a producer and supplier of premium distilled spirits and specialty wheat protein and starch food ingredients. MGP also produces high-quality industrial alcohol for use in both food and non-food applications. It operates in three segments: Distillery Solutions, Branded Spirits Segment, and Ingredient Solutions. Distillery Solutions provides distillery co-products, such as distillers feed, fuel grade alcohol, and corn oil: and warehouse services, including barrel put away, storage, and retrieval services. It derives its revenue from the Distillery Solutions segment.
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.